Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EHC vs SGRY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EHC Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

EHC Overall Winner 6-Pillar Tally: EHC 5 – 1 SGRY Matrix Metrics: EHC 9 – 1 SGRY

As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EHC carries a Unified Composite Score of 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EHC vs SGRY
EHC NYSE Head-to-Head Winner
Encompass Health Corporation Common Stock
Services-Hospitals
$133.65
+1.04% 1D
Market Cap $13.0B
TTM Revenue $6.34B
Forward P/E 19.4x
Beta / 30D Vol -0.10β · 40% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 54.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.8 · SMA20: $135.78 · SMA50: $128.15
SGRY NASDAQ
Surgery Partners, Inc. Common Stock
Services-General Medical & Surgical Hospitals, Nec
$26.78
+0.34% 1D
Market Cap $3.5B
TTM Revenue $3.36B
Forward P/E N/M
Beta / 30D Vol 0.87β · 166% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 24.0 Flow 56.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.5% over 20 days), RSI 84
RSI-14: 84.4 · SMA20: $24.97 · SMA50: $18.56

6-Pillar Scorecard Institutional Category Breakdown (EHC 5 – 1 SGRY)

Columns: Metric · EHC · SGRY
1. Valuation Multiples EHC
Forward P/E 19.4x N/M
Trailing P/E 21.2x N/M
PEG Ratio 0.41x 1.66x
EV / Revenue 2.5x 1.9x
2. Growth & Scale EHC
Revenue Growth (YoY) +8.9% -0.8%
Earnings Growth (YoY) +21.6% +0.0%
TTM Revenue (USD) $6.34B $3.36B
Market Cap $13.0B $3.5B
3. Profitability & Quality EHC
Gross Margin 44.1% 22.2%
Operating Margin 18.4% 13.2%
Net Profit Margin 10.2% -2.6%
Return on Equity (ROE) 25.1% 2.1%
4. Balance Sheet & Cash Flow EHC
Cash Generation (TTM) $457M $203M
Cash Flow Margin 7.2% 6.0%
Net Cash / Leverage $2.73B Net Debt (1.05x D/E) $2.96B Net Debt (1.99x D/E)
Dividend Yield 0.58% None (0.00%)
5. Options & Positioning SGRY
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 27.0% (8th %ile) 62.1% (34th %ile)
Put/Call OI Skew 0.25x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat EHC
OpEx & R&D Intensity 25.7% of Rev ($1.63B) 9.0% of Rev ($302M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EHC (9) vs SGRY (1)
Institutional Metric EHC SGRY Criterion Row Edge
Market Capitalization
Scale
$13.0B $3.5B Larger Scale EHC
Trailing P/E Ratio
Valuation
21.2x N/M Lower Multiple EHC
Forward P/E Ratio
Valuation
19.4x N/M Lower Multiple EHC
Revenue Growth (YoY)
Growth
+8.9% -0.8% Higher Growth EHC
Operating Margin (TTM)
Profitability
18.4% 13.2% Higher Margin EHC
Net Profit Margin
Profitability
10.2% -2.6% Higher Margin EHC
Return on Equity (ROE)
Capital Efficiency
25.1% 2.1% Higher ROE EHC
52-Week Range Position
Momentum
80% ($93–$144) 97% ($11–$27) Stronger Trend SGRY
Beta / 30D Volatility
Risk Regime
-0.10β · 40% Vol 0.87β · 166% Vol Lower Realized Risk EHC
Unified Institutional Score
Composite Signal
52.0 / 100 (HOLD) 29.6 / 100 (SELL) Higher Composite EHC
Trailing 12M Revenue (USD)
Operating Scale
$6.34B $3.36B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.1% 22.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.41x PEG · 2.5x EV/Rev 1.66x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$457M ($2.73B Net Debt (1.05x D/E)) $203M ($2.96B Net Debt (1.99x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGRY +62.37 pp
EHC: +6.06% · SGRY: +68.43%
3M Horizon SGRY +81.44 pp
EHC: +10.53% · SGRY: +91.97%
6M Horizon SGRY +72.52 pp
EHC: +27.33% · SGRY: +99.85%
1Y Horizon SGRY +51.04 pp
EHC: +19.42% · SGRY: +70.46%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EHC Revenue SGRY Revenue EHC Op. Margin SGRY Op. Margin Margin Leader
FY2018 $4.28B $1.77B 13.0% 4.4% EHC
FY2019 $4.61B $1.83B 13.3% 12.9% EHC
FY2020 $3.57B $1.86B 15.8% 9.8% EHC
FY2021 $4.01B $2.23B 13.9% 13.6% EHC
FY2022 $4.35B $2.54B 12.4% 13.6% SGRY
FY2023 $4.80B $2.74B 7.3% 12.0% SGRY
FY2024 $5.37B $3.11B 8.5% 11.2% SGRY
FY2025 $5.94B $3.31B 9.5% 11.8% SGRY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EHC CONSOLIDATION
73d in phase · OBV DISTRIBUTION
Current IV 27.0%
IV Percentile 8th %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGRY SURGE
5d in phase · OBV NEUTRAL
Current IV 62.1%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGRY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EHC Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $13.0B market capitalization and 18.4% operating margin.
OpEx & R&D Reinvestment 25.7% of Rev ($1.63B)
90D Engineering Disclosures 0 Published
SGRY Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.5B market capitalization and 13.2% operating margin.
OpEx & R&D Reinvestment 9.0% of Rev ($302M)
90D Engineering Disclosures 0 Published

Investor FAQ EHC vs SGRY Key Questions & Quantitative Answers

As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EHC carries a Unified Composite Score of 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin). Technically, EHC sits in a Neutral phase (RSI 49.8, CONSOLIDATION options structure) and SGRY sits in a Markup phase (RSI 84.4, SURGE options structure).

EHC leads the Growth & Scale pillar: EHC posts +8.9% YoY revenue growth and +21.6% YoY earnings growth on $6.34B TTM revenue (44.1% gross margin, 18.4% operating margin), compared with SGRY at -0.8% YoY revenue growth and +0.0% YoY earnings growth on $3.36B TTM revenue (22.2% gross margin, 13.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EHC cumulative revenue shifted +38.8% while SGRY shifted +87.0%. In operating R&D and SG&A reinvestment, EHC deploys 25.7% of Rev ($1.63B) (0 90-day corporate R&D disclosures) versus 9.0% of Rev ($302M) (0 disclosures) for SGRY.

EHC screens cheaper on headline valuation multiples. EHC trades at 19.4x Forward P/E, 21.2x Trailing P/E, 0.41x PEG, and 2.5x EV/Revenue (7.2% FCF margin), whereas SGRY trades at N/M Forward P/E, N/M Trailing P/E, 1.66x PEG, and 1.9x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EHC (25.1% ROE) versus SGRY (2.1% ROE) capital efficiency.

In options market volatility and institutional positioning, EHC carries 27.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.10β · 40% Vol realized risk). By comparison, SGRY carries 62.1% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.87β · 166% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.